- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:06 | Silo Pharma highlights PTSD treatment program amid policy shift | 2 | Investing.com | ||
| 13:06 | Silo Pharma highlights PTSD drug program amid policy shift | 1 | Investing.com | ||
| 12:58 | Silo Pharma rückt PTSD-Programm nach politischem Kurswechsel in den Fokus | 1 | Investing.com Deutsch | ||
| 12:36 | Silo Pharma, Inc.: Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics | 238 | GlobeNewswire (Europe) | SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage... ► Artikel lesen | |
| 07.04. | Silo Pharma-Aktie schießt nach europäischer Patent-Zusage in die Höhe | 1 | Investing.com Deutsch | ||
| 07.04. | Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket | 2 | Benzinga.com | ||
| 07.04. | Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline-UnitedHealth, Silo Pharma, Phillips 66 In Focus | 5 | Benzinga.com | ||
| SILO PHARMA Aktie jetzt für 0€ handeln | |||||
| 07.04. | Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know | 1 | Benzinga.com | ||
| 06.04. | Silo Pharma receives European patent approval for stress prevention therapy | 1 | Investing.com | ||
| 06.04. | Silo Pharma, Inc.: Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy | 91 | GlobeNewswire (Europe) | EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:... ► Artikel lesen | |
| 27.03. | Silo Pharma, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 23.02. | Silo Pharma kündigt Aktienrückkaufprogramm über 1 Mio. US-Dollar an - Aktie schießt in die Höhe | 1 | Investing.com Deutsch | ||
| 23.02. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.02. | Silo Pharma authorizes $1M share repurchase program; shares up | 2 | Seeking Alpha | ||
| 23.02. | Silo Pharma, Inc.: Silo Pharma Announces Share Buyback Program | 1 | GlobeNewswire (USA) | ||
| 18.02. | Japan erteilt Patent für PTSD-Therapeutikum von Silo Pharma | 1 | Investing.com Deutsch | ||
| 18.02. | Japan grants patent for Silo Pharma's PTSD treatment | 2 | Investing.com | ||
| 18.02. | Silo Pharma, Inc.: Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio | 2 | GlobeNewswire (USA) | ||
| 30.12.25 | Silo Pharma signs LOI with Allucent for SPC-15 nasal spray clinical trials | 1 | Investing.com | ||
| 30.12.25 | Silo Pharma, Inc.: Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 | 193 | GlobeNewswire (Europe) | Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company")... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,55 | +1,26 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech mit einem Kursziel von 155 US-Dollar auf "Buy" belassen. Die Produktpipeline des Antikörperspezialisten stehe wieder... ► Artikel lesen | |
| AMGEN | 297,85 | -1,33 % | Amgen - Korrektur beendet? | ||
| NOVAVAX | 7,310 | -2,66 % | Is Shah Capital's Criticism of Novavax Fair? A Wall Street Analyst Weighs In | ||
| BIOGEN | 155,00 | +2,87 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| ILLUMINA | 112,52 | -1,52 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,325 | +0,08 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| VIKING THERAPEUTICS | 29,650 | -0,84 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| MAINZ BIOMED | 0,470 | -3,49 % | MAINZ BIOMED N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 12,560 | -1,10 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 47,430 | -0,09 % | Here's What TD Cowen Thinks About Tempus AI Inc (TEM) Stock | ||
| EDITAS MEDICINE | 3,020 | +2,03 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,822 | -3,05 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2026 Financial Results on May 6 | ||
| BIOMARIN PHARMACEUTICAL | 45,660 | 0,00 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,900 | -2,19 % | H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target | ||
| EXELIXIS | 38,195 | +0,12 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen |
Das Unternehmen SILO PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,061 (+11,61 %) liegt der Kurs bei 0,584 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILO PHARMA INC finden Sie auf Wallstreet Online.